Motoharu Seiki

Motoharu Seiki

Auto-generated profile, based on publicly available information

Motoharu Seiki

Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1999 in Japanese Journal of Cancer Research
Verified
Journal Article
Open access
PDF file
THTakeshi Harayama
Takeshi Harayama
EOEiko Ohuchi
Eiko Ohuchi
TATAKANORI AOKI
TAKANORI AOKI
HSHiroshi Sato
Hiroshi Sato
MSMotoharu Seiki
Motoharu Seiki
YOYasunori Okada
Yasunori Okada
Membrane type 1 matrix metalloproteinase (MT1‐MMP) with a transmembrane domain is a new member of the MMP gene family and is expressed on the cell surfaces of many carcinoma cells to activate the zymogen of MMP‐2 (gelatinase A). We have previously reported that MT1‐MMP is released into culture media in a complex form with tissue inhibitor of metalloproteinases 2 (TIMP‐2) from a human breast carcinoma cell line, MDA‐MB‐231, treated with concanavalin A (Con A). In the present study, we further studied the release mechanism of MT1‐MMP. Immunoblot analysis indicated that the amounts of MT1‐MMP in culture media increase with the time of exposure and the concentration of Con A, and those in cell lysates conversely decrease in a similar way. Time‐ and dose‐dependent release of MT1‐MMP into the media was confirmed by a sandwich enzyme immunoassay specific to MT1‐MMP. The molecular weight of the immunoreactive MT1‐MMP in the media was Mr 56,000, which was 4,000‐Mr smaller than that in the cell lysates. Northern blot analysis demonstrated that the mRNA expression level of MT1‐MMP is about 3‐fold enhanced after a 24 h‐exposure to Con A and this is maintained up to 72‐h exposure. The release of MT1‐MMP from the Con A‐treated cells was inhibited by metalloproteinase inhibitors such as EDTA and o‐phenanthroline, but not by MMP inhibitors including TIMP‐1, TIMP‐2 and BB94 or other proteinase inhibitors of serine, cysteine and aspartic proteinases. During the Con A treatment of the cells, cell viability decreased time‐ and dose‐dependently and dead cells reacted positively in the TdT‐mediated dUTP Nick‐End Labeling (TUNEL) method. Con A‐treated MDA cells showed apoptotic morphology when stained with Hoechst dye and hematoxylin and eosin. DNA ladder formation was detected by electrophoresis of the DNA from Con A‐treated MDA cells. These results suggest that MT1‐MMP release from Con A‐treated cells is due to shedding mediated by metalloproteinase(s) other than MMPs, and is associated with apoptosis.

19 January 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
LHLorin Host
Lorin Host
APAlexandra Paye
Alexandra Paye
BDBenoit Detry
Benoit Detry
SBSilvia Blacher
Silvia Blacher
CMCarine Munaut
Carine Munaut
ANAgnes Noel
Agnes Noel
Membrane‐type 4 matrix metalloprotease (MT4‐MMP) expression in breast adenocarcinoma stimulates tumor growth and metastatic spreading to the lung. However, whether these pro‐tumorigenic and pro‐metastatic effects of MT4‐MMP are related to a proteolytic action is not yet known. Through site directed mutagenesis MT4‐MMP has been inactivated in cancer cells through Glutamic acid 249 substitution by Alanine in the active site. Active MT4‐MMP triggered an angiogenic switch at day 7 after tumor implantation and drastically accelerated subcutaneous tumor growth as well as lung colonization in recombination activating gene‐1‐deficient mice. All these effects were abrogated upon MT4‐MMP inactivation. In sharp contrast to most MMPs being primarily of stromal origin, we provide evidence that tumor‐derived MT4‐MMP, but not host‐derived MT4‐MMP contributes to angiogenesis. A genetic approach using MT4‐MMP‐deficient mice revealed that the status of MT4‐MMP produced by host cells did not affect the angiogenic response. Despite of this tumor intrinsic feature, to exert its tumor promoting effect, MT4‐MMP requires a permissive microenvironment. Indeed, tumor‐derived MT4‐MMP failed to circumvent the lack of an host angio‐promoting factor such as plasminogen activator inhibitor‐1. Overall, our study demonstrates the key contribution of MT4‐MMP catalytic activity in the tumor compartment, at the interface with host cells. It identifies MT4‐MMP as a key intrinsic tumor cell determinant that contributes to the elaboration of a permissive microenvironment for metastatic dissemination.

15 September 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SSShinya Sato
Shinya Sato
MNMasatoshi Nakagawa
Masatoshi Nakagawa
TTTakeshi Terashima
Takeshi Terashima
SMSoichiro Morinaga
Soichiro Morinaga
YMyohei miyagi
yohei miyagi
NKNaohiko Koshikawa
Naohiko Koshikawa
Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean ± SD) in more than half of the patients with stage I/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP. Significance: EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.

19 September 2018 in BioTechniques
Verified
Journal Article
Open access
TTTakahisa Takino
Takahisa Takino
HSHiroshi Sato
Hiroshi Sato
MSMotoharu Seiki
Motoharu Seiki
A modified invasion assay using a three-dimensional collagen gel was developed that enables isolation of invasive living cells; it was named the invading cell trapping (iCT) assay. A small cell strainer consisting of a nylon mesh with 40-μm2 pores was used, and collagen gel layers formed across the membrane. Test cells were seeded in the lower gel layer and invasive cells were attracted upward and trapped in the upper gel. After incubation, the collagen gel layers in cell strainers were easily separated and living cells in the gel were counted and analyzed. An advantage of the iCT assay is that it can capture living invasive cells in the upper gel while leaving noninvasive ones in the lower layer. Further enrichment of the two cell populations can be achieved by repeating the assay. Thus, the iCT assay allows comparative analysis of invasive versus noninvasive cells.

1 April 1993 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ABAbraham Blank
Abraham Blank
KYKazunari Yamaguchi
Kazunari Yamaguchi
WBWilliam Blattner
William Blattner
HKHiroyuki Kiyokawa
Hiroyuki Kiyokawa
MSMotoharu Seiki
Motoharu Seiki
KTKiyoshi Takatsuki
Kiyoshi Takatsuki
Abraham Blank, Kazunari Yamaguchi, William Blattner, Hiroyuki Kiyokawa, Motoharu Seiki, Toshiki Watanabe, Shigeo Hino, Kiyoshi Takatsuki; Report of the Fifth In

15 September 2023
Verified
Other
Open access
SSShinya Sato
Shinya Sato
MNMasatoshi Nakagawa
Masatoshi Nakagawa
TTTakeshi Terashima
Takeshi Terashima
SMSoichiro Morinaga
Soichiro Morinaga
YMyohei miyagi
yohei miyagi
NKNaohiko Koshikawa
Naohiko Koshikawa
Cleavage of erythropoietin-producing hepatocellular ephrin receptor A2 (EphA2) triggers malignant progression and yields an N-terminal fragment (EphA2-NF) detectable in sera from patients with pancreatic ductal carcinoma. We established a quantitative automated chemiluminescence immunoassay for EphA2-NF and evaluated serum EphA2-NF levels as a biomarker to diagnose pancreatic ductal carcinoma in the test and validation cohorts. The EphA2-NF value was elevated (above the cutoff: mean ± SD) in more than half of the patients with stage I/II pancreatic ductal carcinoma. Among patients receiving standard chemotherapy for pancreatic ductal carcinoma [gemcitabine plus nab-paclitaxel (GnP)], the median survival time of patients with elevated serum EphA2-NF was half that of patients with values below the cutoff. Patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous pancreatic ductal carcinoma lesion, also show high serum EphA2 levels, which are associated with an increase in pancreatic duct size and the development of pancreatic ductal carcinoma in some cases. IHC showed loss of EphA2-NF staining in IPMN with pancreatic ductal carcinoma, but not in the normal epithelium or IPMN without pancreatic ductal carcinoma, regardless of the histologic grade. These results suggest that EphA2 cleavage is an essential event that occurs very early in pancreatic ductal carcinoma development, and that the consequent release of EphA2-NF can be detected in the serum. Thus, serum EphA2-NF could be a diagnostic biomarker for very early-stage pancreatic ductal carcinoma and pancreatic ductal carcinoma development from high-risk IPMN and as a prognostic biomarker after chemotherapy with GnP.Significance:EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.